Cardiac resynchronization therapy, central sleep apnea, and Cheyne-Stokes respiration in chronic heart failure patients: Reply  by Stellbrink, Christoph et al.
Please note: Dr. Rajamannan is an inventor on a patent assigned to the Mayo Clinic
titled “Method for Slowing Heart Valve Degeneration.” The Mayo Clinic owns all
rights to the patent.
REFERENCES
1. Bonow RO, Braunwald E. Valvular heart disease. In: Zipes DP, Libby
P, Bonow RO, Braunwald E, editors. Heart Disease: A Textbook of
Cardiovascular Medicine. 7th edition. Philadelphia, PA: Elsevier
Science, 2004:1553–621.
2. Boon A, Cheriex E, Lodder J, Kessels F. Cardiac valve calcification:
characteristics of patients with calcification of the mitral annulus or
aortic valve. Heart 1997;78:472–4.
3. Nair CK, Subdhakaran C, Aronow WS, et al. Clinical characteristics
of patients younger than 60 years with mitral annular calcium:
comparison with age and sex matched control subjects. Am J Cardiol
1984;54:1286–7.
4. Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum
lipids, calcium and phosphorus, diabetes mellitus, aortic valve stenosis:
a history of systemic hypertension with presence or absence of mitral
annular calcium in persons older than 62 years in a long-term health
care facility. Am J Cardiol 1987;59:381–2.
5. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med
1999;340:115–26.
6. Roberts WC. The senile cardiac calcification syndrome. Am J Cardiol
1986;58:572–4.
7. Roberts WC. Morphologic features of the normal and abnormal mitral
valve. Am J Cardiol 1983;51:1005–28.
8. Rajamannan NM, Subramaniam M, Springett M, et al. Atorvastatin
inhibits hypercholesterolemia-induced cellular proliferation and bone
matrix production in the rabbit aortic valve. Circulation 2002;105:
2260–5.
9. Adler Y, Koren A, Fink N, et al. Association between mitral annulus
calcification and carotid atherosclerotic disease. Stroke 1998;29:
1833–7.
10. Adler Y, Zabarski RS, Vaturi M, et al. Association between mitral
annulus calcification and aortic atheroma as detected by transesopha-
geal echocardiographic study. Am J Cardiol 1998;81:784–6.
11. Adler Y, Vaturi M, Wiser I, et al. Nonobstructive aortic valve calcium
as a window to atherosclerosis of the aorta. Am J Cardiol 2000;86:
68–71.
Letters to the Editor
Cardiac Resynchronization Therapy,
Central Sleep Apnea, and Cheyne-Stokes
Respiration in Chronic Heart Failure Patients
We congratulate Sinha et al. (1) for their interesting and innova-
tive report in JACC on the therapeutic effect of biventricular pacing
on central sleep apnea (CSA). A few questions remain: the title
suggests some information about Cheyne-Stokes respiration
(CSR), which is not equivalent to CSA; however, results are
lacking. Were all apnea/hypopnea events central in nature or did
some also have obstructive or mixed events? Completely blinded
serial scoring is difficult in patients undergoing an intervention
such as an implantation device, and therefore a bias in visual
scoring might be possible. We would be interested in learning
some additional objective values such as desaturation index or time
in apnea. This would be of greater value than minimum SaO2 in
their Table 3.
In their discussion, the investigators state that CSA is related to
heart failure, a statement that contrasts to similar findings on
exercise and echocardiography in both groups. In view of this, how
do the researchers explain the dramatic effects of cardiac resyn-
chronization therapy (CRT) on CSA when the benefit of CRT (on
echocardiography and exercise) is equal in patients with and
without CSA? Moreover, the effect of CRT on sleep apnea, as
described by Sinha et al. (1), is huge and much higher than in our
experience and even higher than after cardiac transplantation (2,3).
In these reports, cyclic respiration/CSR was abolished, but sleep
apnea persisted or got worse in a considerable number of patients.
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REPLY
We thank Dr. Scharf and colleagues for their valuable comments
to our study on central sleep apnea (CSA) and cardiac resynchro-
nization therapy (CRT) (1). Importantly, all patients in our study
had CSA and no evidence of obstructive sleep apnea (OSA).
Because apnea occurred with a periodic pattern in patients with
known advanced heart failure we believe that the breathing pattern
can be classified as CSA although timing of arousals relative to
respiratory events could not be evaluated with the polygraphy
system used. We agree that desaturation index, breathing cycle
length, and time in apnea add important information and have
summarized these data in Table 1.
We have now studied more patients with mixed apnea or OSA
and found less improvement in mixed apnea and no significant
effect in OSA (2). Therefore, we believe that CRT works mainly
on CSA by improving cardiac hemodynamics.
The notion that CSA is related to the severity of heart failure
was derived from previous studies (3) and not from our data. We
caution that our results refer to a small group of patients with short
Table 1. Additional Parameters Obtained by Polygraphy Before
and During CRT
Pre-CRT On CRT p Value
Desaturation index 23  10.6 9.6  5 0.002
Cycle length (s) 60.6  5.7 45.8  2.2 0.002
Ventilation/apnea length
ratio
1.15  0.12 0.42  0.1 0.001
CRT  cardiac resynchronization therapy.
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follow-up. Differences in functional response between CSA and
non-CSA patients may only become evident later or in larger
patient cohorts. The studies on posttransplant patients (4,5) had
longer follow-up times but also showed similar improvement in
both CSA and non-CSA patients. The effect of CRT on CSA in our
study seemed larger than in these studies, which may be explained by
the fact that OSA patients were not included and new OSA was not
observed in our patients during CRT. It is yet unclear why OSA
develops in some patients after cardiac transplantation.
Finally, all our patients had ventricular conduction disturbance,
which qualified them for CRT. The incidence of ventricular
conduction disturbance has not been reported in previous trials on
CSA. The association of CSA and cardiac rhythm disturbances
such as atrial fibrillation has recently gained interest (6). We hope
that our data may stimulate further research into this direction.
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Effects of Percutaneous
Left Atrial Appendage
Transcatheter Occlusion (PLAATO)
on Left Atrial Structure and Function
With great interest we read the study by Hanna et al. (1) on left
atrial (LA) structure and function after percutaneous left atrial
appendage transcatheter occlusion (PLAATO). In 11 patients,
adequate seal of the left atrial appendage (LAA) is reported
without affecting LA function or the left upper pulmonary vein.
The PLAATO had first been performed in 25 dogs in sinus
rhythm. This study by Nakai et al. (2) has been the scientific basis
for implanting the device in humans (1,3,4). Although this
technique appears very attractive, there are several points of
criticism concerning study design, data collection, and interpreta-
tion of the results.
1. The LA diameter is reported only at baseline. Furthermore,
peak mitral E-wave velocity and diameter, peak systolic, and
diastolic velocities of the left upper pulmonary vein were not
registered in every patient at baseline, 1, and 6 months.
Overall, only 3 of the 11 patients (cases 1, 2, and 5) had all
measurements completed. Thus, conclusions based on frag-
mentary data in this small patient population are limited.
2. Concerning the importance of the LAA as a hormone-
releasing site, the study lacks information about levels of
natriuretic peptides before and after PLAATO.
3. The investigators state that PLAATO does not interfere with
LA function because there was no significant change in
transmitral or pulmonary venous flow. However, no LA
pressure measurements are reported. Because LAA occlusion
may result in reduced atrial compliance, data on LA diameter
and volume during follow-up would be of interest.
4. Hanna et al. conclude that the PLAATO device does not
result in any detrimental anatomic or physiologic changes to
adjacent structures. Besides left upper pulmonary vein and
mitral valve, however, the circumflex branch of the left
coronary artery lies adjacent to the LAA base. Therefore,
information on the development of anginal chest pain after
PLAATO is of importance.
5. The finding of minimal flow around the PLAATO device in
every patient immediately after implantation and at follow-up
is in contrast to complete LAA occlusion found at necropsy in
dogs of the initial study by Nakai et al. (2). In that study, stability
of the device and completeness of LAA occlusion was assessed in
formalin-fixed hearts. Formalin fixation, however, results in
tissue-shrinkage (5). Thus, complete LAA closure and device
stability may have been due to an artificial decrease of the LAA
size. Moreover, the mode of conservation may explain the
discrepancy between complete LAA occlusion in all dogs at the
postmortem study and the small leaks around the device in living
dogs immediately after the procedure and during follow-up.
6. Residual flow around the PLAATO device does not preclude
thrombus formation in the LAA. However, residual leaks in
case of thrombosis may be a new potential mechanism for
embolic events as in patients with incomplete surgical LAA
ligation (6). Therefore, it would be of great interest whether
patients with residual leaks experienced embolic events during
follow-up.
Before recommending PLAATO as a therapeutic option in
atrial fibrillation patients, more evidence about the long-term
effects of this procedure is required.
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